Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb, 96 Week, Randomized, Open-label Multicenter, Parallel Group, Repeat Dose Study to Evaluate the Safety, Tolerability, PK and Antiviral Effect of Different Doses and Regimens of GW873140 in Combination With Kaletra (Lopinavir and Ritonavir) in HIV-1 Infected Antiretroviral Therapy naïve Subjects

NCT00102778 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT00102778
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00102778 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb, 96 Week, Randomized, Open-label Multicenter, Parallel Group, Repeat Dose Study to Evaluate the Safety, Tolerability, PK and Antiviral Effect of Different Doses and Regimens of GW873140 in Combination With Kaletra (Lopinavir and Ritonavir) in HIV-1 Infected Antiretroviral Therapy naïve Subjects
Lead sponsor
ViiV Healthcare
Phase
Phase 2
Overall status
Terminated
Start date
December 31, 2004
Completion date
September 30, 2007
Enrollment
175
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infection, infection, human immunodeficiency virus i